Marinus Pharmaceuticals, Inc., a Branford, Conn.-based developer of a neuroactive steroid, raised an additional $21m funding in Series C financing.
Backers include Domain Associates, RusnanoMedInvest, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners.
Led by Christopher M. Cashman, Chief Executive Officer, Marinus has developed Ganaxolone, a neuroactive steroid for the treatment of neurological and psychiatric indications which was licensed in 2003 from Purdue Pharma and has been reformulated and optimized using its patented nanotechnology platform.
The funding will enable the company to conduct further clinical development in Epilepsy and other CNS indications.
FinSMEs
07/01/2013